- Anchor investor bidding date is Friday, July 11, 2025
- Bid /Offer opening date – Monday, July 14, 2025, and closing date –Wednesday, July 16, 2025
- Bids can be made for a minimum of 26 equity shares and in multiples of 26 equity shares thereafter
NE BUSINESS BUREAU
AHMEDABAD, JUY 10
Bengaluru-based Anthem Biosciences has set a price band of ₹540-570 per share for its upcoming initial public offering (IPO), scheduled to open for subscription on Monday, July 14 and close on Wednesday, July 16. Anchor investor bidding will begin on Friday, July 11. The IPO is purely an offer-for-sale by existing shareholders worth ₹3,395 crore.
Bids can be made for a minimum of 26 equity shares and multiples of 26 equity shares thereafter.
The IPO is entirely an offer for sale (OFS) by existing shareholders, meaning no fresh capital will be infused into the company
Viridity Tone LLP, backed by the private equity firm True North and holding a 7.93% stake in Anthem Biosciences, is the largest selling shareholder, offloading shares worth ₹ 1,325 crore. Other selling shareholders include Portsmouth Technologies and individuals Malay J. Barua, Rupesh N. Kinekar, and Satish Sharma, each selling shares worth ₹ 320 crore.
Anthem Biosciences has formed a strategic alliance with DavosPharma, an affiliate of Portsmouth LLC, which owns a 3.74% stake in the company. This partnership has expanded its client base in the U.S., bringing in 89 new customers, including 83 emerging biotech firms, over the past three fiscal years.
Founded in 2006, Anthem Biosciences is a technology-led and innovation-focussed CRDMO, offering end-to-end services across the drug discovery, development, and manufacturing value chain. The company serves a wide range of global clients, including emerging biotech firms and established pharmaceutical companies.
Anthem is known for its expertise in fermentation-based active pharmaceutical ingredients (APIs), manufacturing products such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
All facilities adhere to current Good Manufacturing Practices (cGMP) and are accredited by prominent international regulatory authorities, including the U.S. FDA, ANVISA (Brazil), TGA (Australia), and PMDA (Japan).
As of March 2025, Anthem Biosciences serves over 550 clients across its contract research, development, and manufacturing (CRDMO) and specialty ingredients segments in more than 44 countries. The company’s top five customers accounted for 70.92% of its revenue in FY25.
The company operates three manufacturing facilities, with Unit I located in Bommasandra and Units II and III in Harohalli. The third unit is under construction and expected to be completed by the first half of FY26. All facilities adhere to cGMP standards and have received accreditation from major global regulatory bodies, including the US FDA and Japan’s PMDA.
Financially, Anthem Biosciences reported a net profit of ₹451.3 crore for the fiscal year ended March 2025, reflecting a growth of 22.9% from the previous year. Revenue increased by 30%, reaching ₹1,844.6 crore.
The Equity Shares of the Company are proposed to be listed on BSE Limited and the National Stock Exchange of India Limited.
JM Financial Limited, Citigroup Global Markets India Private Limited, JP Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited are the Book Running Lead Managers to the Offer.
